00833 ALLTRONICS
- 0.500
- -0.010-1.96%
ALLTRONICS News
華訊：二零二三年年報
ALLTRONICS To Go Ex-Dividend On June 7th, 2024 With 0.02 HKD Dividend Per Share
April 1st - $ALLTRONICS(00833.HK)$ is trading ex-dividend on June 7th, 2024. Shareholders of record on June 11th, 2024 will receive 0.02 HKD dividend per share on June 28th, 2024. The ex-dividend
Huaxun (00833) Announces Annual Results Profit attributable to shareholders of HK$108 million, a year-on-year decrease of 3.24%, and final interest of HK2 HK cents per share
According to the Zhitong Finance App, Huaxun (00833) announced the results for the year ended December 31, 2023. The Group's revenue was HK$1,347 million, a year-on-year decrease of 22.21%; profit attributable to shareholders was HK$108 million, a year-on-year decrease of 3.24%; profit per share was 22.92 HK cents; and final interest was HK$2 per share. According to the announcement, the decline in turnover was mainly due to a decrease in sales of electronic products.
ALLTRONICS: ANNOUNCEMENT OF FINAL RESULTS FOR THE YEAR ENDED 31 DECEMBER 2023
ECCOM (00833.HK) held a board meeting on March 28 to consider and approve the annual results
Glonghui March 14 | Huaxun (00833.HK) announced that it will hold a board meeting on March 28, 2024 (Thursday) to consider and approve the annual results of the company and its subsidiaries for the year ended 31 December 2023, the proposed final dividend (if applicable), and to deal with other matters.
Yuanda Pharmaceutical (00512): The new drug marketing application for the global innovative hormone nano-suspension eye drops GPN00833 was approved by the US FDA
Yuanda Pharmaceutical (00512) issued an announcement, and the group's partner in the field of ophthalmology, Taixin Pharmaceutical Co., Ltd. announced its use...
Alltronics Arm Reaches Settlement Deal With Dongguan Hongjun Packaging Products
Alltronics Holdings (HKG:0833) said subsidiary Shenzhen Allcomm has reached a settlement agreement with supplier and plaintiff Dongguan Hongjun Packaging Products. Major terms of the deal state that a
Huaxun (00833): Shenzhen Dexun signed a settlement agreement with the plaintiff
Huaxun (00833) announced that Shenzhen Dexun has signed a settlement with the plaintiff on October 31, 2023...
Yuanda Pharmaceutical (00512) completed the phase III clinical trial of GPN00833, a hormone used for anti-inflammatory and analgesic analgesia, to enroll the first patient
Yuanda Pharmaceutical (00512) announced that the group's hormone nano suspension eye drops for anti-inflammatory and analgesic analgesia GPN0083...
ALLTRONICS: Interim Report 2023
Express News | The Securities Regulatory Commission announced that as of the end of June, 12 consulting agencies had been suspended and new clients had been added
ALLTRONICS To Go Ex-Dividend On September 25th, 2023 With 0.02 HKD Dividend Per Share
August 31st - $ALLTRONICS(00833.HK)$ is trading ex-dividend on September 25th, 2023. Shareholders of record on September 26th, 2023 will receive 0.02 HKD dividend per share on October 26th, 2023.
Huaxun (00833) Announces Interim Results, Earnings of HK$729 million decreased 15% year-on-year and distributed 2 HK cents per share
Huaxun (00833) announced its 2023 interim results, with revenue of about HK$729 million, a year-on-year decrease of 15%; the public...
ALLTRONICS: ANNOUNCEMENT OF UNAUDITED INTERIM RESULTS FOR THE SIX MONTHS ENDED 30 JUNE 2023
Huaxun (00833.HK) will hold a board meeting on August 30 to approve interim results
GLONGHUI, August 15, 丨Huaxun (00833.HK) announced that the board meeting will be held on August 30, 2023 to review and approve the company's and its subsidiaries's interim results and publication for the six months ended June 30, 2023, and consider the issuance and payment of interim dividends (if applicable).
ALLTRONICS: DATE OF BOARD MEETING
Huaxun (00833): The court has not handed down any judgment on the retrial lawsuit relating to Shenzhen Dexun
Zhitong Finance App News, Huaxun (00833) issued an announcement. Shenzhen Dexun has been informed by the legal adviser handling the legal lawsuit that the retrial has been carried out on July 11, 2023, and that the legal adviser has also represented Shenzhen Dexun in the retrial. During the retrial, the court ordered an on-site inventory and inspection of the finished products, semi-finished products and raw materials relating to the case at the plaintiff's place (this inspection). Shenzhen Dexun, the plaintiff and the court are negotiating arrangements for this inspection. As of the date of this announcement, the court has not handed down any judgment on retrial.
ALLTRONICS To Go Ex-Dividend On June 6th, 2023 With 0.02 HKD Dividend Per Share
June 3rd - $ALLTRONICS(00833.HK)$ is trading ex-dividend on June 6th, 2023. Shareholders of record on June 7th, 2023 will receive 0.02 HKD dividend per share on June 29th, 2023. The ex-dividend da
ECCOM: 2022 Annual Report
Yuanda Pharmaceutical's (00512) China phase III clinical trial application for global innovative ophthalmic drug GPN00833 received implied approval from the Drug Administration
According to the Zhitong Finance App, Yuanda Pharmaceutical (00512) announced that the group's application for a phase III clinical trial of the group's anti-inflammatory and analgesic hormone nano-suspension eye drops GPN00833 (APP13007) has recently obtained implied clinical trial approval from the China Drug Administration. This is an important development in the group's research and development in the field of ophthalmic disease treatment. According to reports, GPN00833 (APP13007) is an anti-inflammatory analgesic hormone nano-mixed eye drop. Its main active ingredient, clobetasol propionate, is a potent glucocorticoid with effective local anti-inflammatory activity
Analysis
Price Target
No Data
